OBJECTIVE: To determine the rates and causes of first antiretroviral treatment changes in HIV-infected adults in Côte d'Ivoire. METHODS: We evaluated adults who initiated antiretroviral treatment in an outpatient clinic in Abidjan. We recorded baseline and follow-up data, including drug prescriptions and reasons for changing to alternative first-line regimens (drug substitution for any reason but failure) or second-line regimens (switch for failure). RESULTS: Two thousand and twelve HIV-infected adults (73% women) initiated antiretroviral treatment. At baseline, 9% of all patients were on treatment for tuberculosis and 3% of women were pregnant. First-line antiretroviral treatment consisted of two nucleoside reverse transcriptase inhibitors (58% stavudine-lamivudine, 42% zidovudine-lamivudine) and efavirenz (63%), nevirapine (32%) or indinavir (5%). Median follow-up time was 16.9 months. During this time, 205 (10%) patients died and 261 (13%) were lost to follow-up. Overall, the rate of treatment modifications was 20.7/100 patient-years. The most common modifications were drug substitutions for intolerance (12.4/100 patient-years), pregnancy (4.5/100 patient-years) and tuberculosis (2.5/100 patient-years). The rates of intolerance-related substitutions were 17.9/100 patient-years for stavudine, 6.3/100 patient-years for nevirapine, 3.9/100 patient-years for zidovudine and 0.1/100 patient-years for efavirenz. Twenty percent of efavirenz substitutions resulted from pregnancy and 18% of nevirapine substitutions were related to tuberculosis treatment. CONCLUSION: During the first months following antiretroviral treatment initiation, a third of all treatment changes occurred for reasons other than intolerance to the drug or treatment failure. In Africa, drug forecasting is crucial to ensuring the success of HIV treatment programmes. Drugs that do not require interruptions during pregnancy or tuberculosis treatment should be made more readily available as first-line drugs in sub-Saharan Africa.
OBJECTIVE: To determine the rates and causes of first antiretroviral treatment changes in HIV-infected adults in Côte d'Ivoire. METHODS: We evaluated adults who initiated antiretroviral treatment in an outpatient clinic in Abidjan. We recorded baseline and follow-up data, including drug prescriptions and reasons for changing to alternative first-line regimens (drug substitution for any reason but failure) or second-line regimens (switch for failure). RESULTS: Two thousand and twelve HIV-infected adults (73% women) initiated antiretroviral treatment. At baseline, 9% of all patients were on treatment for tuberculosis and 3% of women were pregnant. First-line antiretroviral treatment consisted of two nucleoside reverse transcriptase inhibitors (58% stavudine-lamivudine, 42% zidovudine-lamivudine) and efavirenz (63%), nevirapine (32%) or indinavir (5%). Median follow-up time was 16.9 months. During this time, 205 (10%) patients died and 261 (13%) were lost to follow-up. Overall, the rate of treatment modifications was 20.7/100 patient-years. The most common modifications were drug substitutions for intolerance (12.4/100 patient-years), pregnancy (4.5/100 patient-years) and tuberculosis (2.5/100 patient-years). The rates of intolerance-related substitutions were 17.9/100 patient-years for stavudine, 6.3/100 patient-years for nevirapine, 3.9/100 patient-years for zidovudine and 0.1/100 patient-years for efavirenz. Twenty percent of efavirenz substitutions resulted from pregnancy and 18% of nevirapine substitutions were related to tuberculosis treatment. CONCLUSION: During the first months following antiretroviral treatment initiation, a third of all treatment changes occurred for reasons other than intolerance to the drug or treatment failure. In Africa, drug forecasting is crucial to ensuring the success of HIV treatment programmes. Drugs that do not require interruptions during pregnancy or tuberculosis treatment should be made more readily available as first-line drugs in sub-Saharan Africa.
Authors: O Kirk; J Gerstoft; C Pedersen; H Nielsen; N Obel; T L Katzenstein; L Mathiesen; J D Lundgren Journal: HIV Med Date: 2001-01 Impact factor: 3.180
Authors: A d'Arminio Monforte; A C Lepri; G Rezza; P Pezzotti; A Antinori; A N Phillips; G Angarano; V Colangeli; A De Luca; G Ippolito; L Caggese; F Soscia; G Filice; F Gritti; P Narciso; U Tirelli; M Moroni Journal: AIDS Date: 2000-03-31 Impact factor: 4.177
Authors: A Mocroft; M Youle; A Moore; C A Sabin; S Madge; A C Lepri; M Tyrer; C Chaloner; D Wilson; C Loveday; M A Johnson; A N Phillips Journal: AIDS Date: 2001-01-26 Impact factor: 4.177
Authors: Lara R Fairall; Max O Bachmann; Goedele M C Louwagie; Cloete van Vuuren; Perpetual Chikobvu; Dewald Steyn; Gillian H Staniland; Venessa Timmerman; Mpumelelo Msimanga; Chris J Seebregts; Andrew Boulle; Ralph Nhiwatiwa; Eric D Bateman; Merrick F Zwarenstein; Ronald D Chapman Journal: Arch Intern Med Date: 2008-01-14
Authors: Besigin Tonwe-Gold; Didier K Ekouevi; Ida Viho; Clarisse Amani-Bosse; Siaka Toure; Patrick A Coffie; François Rouet; Renaud Becquet; Valériane Leroy; Wafaa M El-Sadr; Elaine J Abrams; François Dabis Journal: PLoS Med Date: 2007-08 Impact factor: 11.069
Authors: Antoine Jaquet; Mariam Mama Djima; Patrick Coffie; Henri Die Kacou; Serge P Eholie; Eugene Messou; Albert Minga; Calixte Guehi; Jean Claude Yavo; Emmanuel Bissagnene; Francois Dabis; Didier K Ekouevi Journal: Pharmacoepidemiol Drug Saf Date: 2011-07-07 Impact factor: 2.890
Authors: Eric N Ouattara; Xavier Anglaret; Angela Y Wong; Jennifer Chu; Heather E Hsu; Christine Danel; Serge Eholié; Raoul Moh; Delphine Gabillard; Rochelle P Walensky; Kenneth A Freedberg Journal: AIDS Date: 2012-03-13 Impact factor: 4.177
Authors: Rochelle P Walensky; Ethan D Borre; Linda-Gail Bekker; Emily P Hyle; Gregg S Gonsalves; Robin Wood; Serge P Eholié; Milton C Weinstein; Xavier Anglaret; Kenneth A Freedberg; A David Paltiel Journal: Ann Intern Med Date: 2017-08-29 Impact factor: 51.598